A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " CLEA Japan, Inc.

CLEA Japan, Inc.

Table of Contents

Nippon Crea is a main supplier of laboratory animals, as well as a non-clinical CRO. Various disease models are available.

The company has established an integrated in-house platform for animal quality control and testing. They have a wide range of client bases for research in immunology and metabolic related diseases.

Features of CLEA Japan, Inc.’s Non-Clinical Study Services

Comprehensive testing Platform based on laboratory animals

Nippon Crea can provide a comprehensive end-to-end support for non-clinical studies as a long-standing lab animals/ lab material supplier and also can perform in vivo studies and report preparation.

The company has a platform that allows clients to involve from the early stage study designing, such as test item planning, animal preparation, feed adjustment, and cage setup.

Nippon Crea ensures the quality and reliability of its contract studies as they have their own lab facility for in-house testing.

With a proven track record in area of regenerative medicine, the company is widely recognized as a reliable partner in advanced research.

Flexible support for both pharmacology and pharmacokinetics

Nippon Crea supports both pharmacodynamic and pharmacokinetic studies, offering comprehensive assistance from the research stage to practical applications.

In addition to efficacy evaluation in animal models, they provide a full range of ADME assessments— absorption, distribution, metabolism, and excretion.

By handling every step from experimental design to data analysis and GLP-compliant reporting, Nippon Crea provides precise and goal-oriented support that is tailored to each stage of the drug discovery process.

Animal welfare and quality management by international standards

Fully accredited by AAALAC International, Nippon Crea is compliant with global standards for animal welfare and research ethics.

Consistent quality control and traceability throughout breeding and reproduction processes ensure high reproducibility in their non-clinical studies.

They can also provide reliable testing platform with GLP standard for studies for pharmaceuticals and regenerative medicine, which has strict regulatory environment.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Example of a Disease Model Available at CLEA Japan, Inc.

Parkinson’s Disease Model Using 6-OHDA

For Parkinson’s disease—a representative neurodegenerative disorder—Nippon Crea offers a model using 6-hydroxydopamine (6-OHDA).

This model selectively damages dopaminergic neurons in the midbrain, reproducing symptoms such as tremors and motor dysfunctions.

It is applicable to preclinical studies aimed for investigating disease pathology and exploring novel therapeutic approaches, and is also available as a part of the company’s non-clinical contract study services.

Reference: https://www.clea-japan.com/promotion/previous_service/parkinson

Non-Clinical Case Study byCLEA Japan, Inc.

Microbiome Study Support Utilizing Gut Microbiota

Nippon Crea also provides microbiome studies focusing on the correlation between gut microbiota, immune function, and many other symptoms of the disease.

They can support the discovery of disease biomarkers, pharmaceuticals and functional foods.

Nippon Crea offers flexible study designs tailored to specific research needs. Clients can expect thorough protocol consultation, study execution and timely reporting. This can also be utilized at the initial screening stage as a non-GLP study.

Reference: https://www.clea-japan.com/products/service/item_c0050

Corporate Information

Address	1-2-7 Higashiyama, Meguro-ku, Tokyo, Japan
Tel	03-5704-7011
Website	https://www.clea-japan.com/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us